Eric J. Small, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Eric J. Small, MD

Clinical Professor, Departments of Medicine and Urology; and Chief, Department of Medicine/Division of Hematology/Oncology, UCSF
Deputy Director; Associate Director, Clinical Sciences; Program Leader, Prostate Cancer Program, UCSF Helen Diller Family Comprehensive Cancer Center

Doris and Donald Fisher Distinguished Professorship in Clinical Cancer Research;
Stanford W. Ascherman and Norman R. Ascherman Endowed Chair, UCSF

Phone: (415) 476-4616 (appts)
Box 1711, UCSF
San Francisco, CA 94143-1711

View on UCSF Profiles

Education

Stanford University, Stanford, CA, BS, 1980, Biology
Case Western Reserve University of Medicine, Cleveland, Ohio, MD, 1985, Medicine
Beth Israel Hospital, Boston, MA, Internship and Residency, 1988, Internal Medicine
University of California San Francisco, CA, Fellowship, 1991, Hematology/Oncology


Professional Experience

  • 1982-1983
    Pathology Fellowship, Department of Pathology, Case Western Reserve Univ., Cleveland, OH
  • 1985-1988
    Internal Medicine Internship and Residency Training Program, Beth Israel Hospital, Boston, MA
  • 1988-1989
    Clinical Fellow, Cancer Research Institute, UCSF, San Francisco, CA
  • 1989-1991
    Research Fellow, Cancer Research Institute, (Dr. Marc Shuman) UCSF, San Francisco, CA
  • 1991-1997
    Assistant Clinical Professor of Medicine, UCSF, San Francisco, CA
  • 1991-present
    Head, Urologic Medical Oncology, Division of Hematology/Oncology, UCSF, San Francisco, CA
  • 1996-present
    Co-Director, Urologic Oncology Program, UCSF, San Francisco, CA
  • 1997-2001
    Associate Clinical Professor of Medicine and Urology, UCSF, San Francisco, CA
  • 1999-present
    Chair, Genitourinary Committee, Cancer and Leukemia Group B (CALGB)
  • 2001-present
    Professor in Residence of Medicine and Urology, UCSF, San Francisco, CA
  • 2007-2009
    Interim Chief, Division of Hematology and Oncology, UCSF, San Francisco, CA
  • 2007-present
    Director, Investigational Trials Resource, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2009-present
    Chief, Division of Hematology/Oncology, UCSF, San Francisco, CA
  • 2009-present
    Deputy Director and Director of Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center

Honors & Awards

  • 1978
    Biomedical Research Grant, The Jackson Laboratory, Bar Harbour, ME
  • 1980
    NIH Research Support Grant, Case Western Reserve University, Cleveland, OH
  • 1984
    Alpha Omega Alpha Honor Medical Society
  • 1997
    Prostate Cancer Foundation Therapy Consortium
  • 2006-present
    Stanford W. and Norman R. Ascherman Endowed Chair

Selected Publications

  1. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18.
    View on PubMed
  2. Wei XX, Fong L, Small EJ. Prospects for the use of ipilimumab in treating advanced prostate cancer. Expert Opin Biol Ther. 2016 Jan 25; 1-12.
    View on PubMed
  3. Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw. 2016 Jan; 14(1):19-30.
    View on PubMed
  4. Crawford ED, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, Small EJ, Shore ND, Ferrari A. Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. Can J Urol. 2015 Dec; 22(6):8048-55.
    View on PubMed
  5. Wei XX, Fong L, Small EJ. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. Expert Rev Vaccines. 2015 Dec; 14(12):1529-41.
    View on PubMed
  6. Kaplan CP, Nápoles AM, Narine S, Gregorich S, Livaudais-Toman J, Nguyen T, Leykin Y, Small EJ. Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients. Contemp Clin Trials. 2015 Oct 1.
    View on PubMed
  7. Kim HL, Halabi S, Li P, Mayhew G, Simko J, Nixon AB, Small EJ, Rini B, Morris MJ, Taplin ME, George D. A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). EBioMedicine. 2015 Nov; 2(11):1814-20.
    View on PubMed
  8. Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Sep; 3(9):1008-16.
    View on PubMed
  9. Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern CH, Shore ND. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015 Sep 1; 21(17):3862-9.
    View on PubMed
  10. Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, Youngren J, Paris P, Thomas G, Small EJ, Wang Y, Gleave ME, Collins CC, Chi KN. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015 May 15; 21(10):2315-24.
    View on PubMed
  11. Halabi S, Rini BI, Escudier B, Stadler WM, Small EJ. Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint? Cancer. 2015 Jun 1; 121(11):1906.
    View on PubMed
  12. GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher TC, Hall SJ, Kantoff PW, Higano CS, Small EJ, Gardner TA, Bailey K, Vu T, DeVries T, Whitmore JB, Frohlich MW, Trager JB, Drake CG. Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clin Cancer Res. 2015 Aug 15; 21(16):3619-30.
    View on PubMed
  13. Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ. Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. J Clin Oncol. 2015 Apr 20; 33(12):1356-63.
    View on PubMed
  14. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb; 16(2):152-60.
    View on PubMed
  15. Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clin Genitourin Cancer. 2015 Jun; 13(3):e191-8.
    View on PubMed
  16. Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 2015 Apr 1; 121(7):1025-31.
    View on PubMed
  17. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76.
    View on PubMed
  18. Small EJ. Can targeting the androgen receptor in localized prostate cancer provide insights into why men with metastatic castration-resistant prostate cancer die? J Clin Oncol. 2014 Nov 20; 32(33):3689-91.
    View on PubMed
  19. Aggarwal RR, Small EJ. Small-cell/neuroendocrine prostate cancer: a growing threat? Oncology (Williston Park). 2014 Oct; 28(10).
    View on PubMed
  20. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014 Nov; 106(11).
    View on PubMed

Go to UCSF Profiles, powered by CTSI